The estimated Net Worth of Patrick J Mcenany is at least $107 Million dollars as of 30 January 2024. Mr. Mcenany owns over 143,000 units of Catalyst Pharmaceuticals Inc stock worth over $88,119,862 and over the last 21 years he sold CPRX stock worth over $15,950,086. In addition, he makes $3,371,560 as Chairman of the Board, President und Chief Executive Officer at Catalyst Pharmaceuticals Inc.
Sign up
Mr. McEnany CPRX stock SEC Form 4 insiders trading
Patrick has made over 62 trades of the Catalyst Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 143,000 units of CPRX stock worth $2,782,780 on 30 January 2024.
The largest trade he's ever made was selling 1,027,611 units of Catalyst Pharmaceuticals Inc stock on 13 September 2022 worth over $15,835,486. On average, Patrick trades about 47,532 units every 70 days since 2003. As of 30 January 2024 he still owns at least 4,528,256 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Mr. Mcenany stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patrick McEnany biography
Patrick James McEnany is the Chairman of the Board, President, Chief Executive Officer of Catalyst Pharmaceutical Partners, Inc. Mr. McEnany has been our CEO and a director since our formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on an emeritus board of directors of the Jackson Health Foundation and on the board of directors of the Humane Society of Greater Miami, and over the last 30 years has served as a director for numerous public companies. The Board believes the characteristics that qualify Mr. McEnany as a director to serve on our Board include his long-term experience in the pharmaceutical industry and his extensive business leadership experience.
What is the salary of Patrick McEnany?
As the Chairman of the Board, President und Chief Executive Officer of Catalyst Pharmaceuticals Inc, the total compensation of Patrick McEnany at Catalyst Pharmaceuticals Inc is $3,371,560. There are no executives at Catalyst Pharmaceuticals Inc getting paid more.
How old is Patrick McEnany?
Patrick McEnany is 72, he's been the Chairman of the Board, President und Chief Executive Officer of Catalyst Pharmaceuticals Inc since 2006. There are 3 older and 13 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
What's Patrick McEnany's mailing address?
Patrick's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, , CORAL GABLES, FL, 33134.
Insiders trading at Catalyst Pharmaceuticals Inc
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany und Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
What does Catalyst Pharmaceuticals Inc do?
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
What does Catalyst Pharmaceuticals Inc's logo look like?
Complete history of Mr. Mcenany stock trades at Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc executives and stock owners
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Patrick McEnany,
Chairman of the Board, President, Chief Executive Officer -
Steven Miller,
Chief Operating Officer, Chief Scientific Officer -
Gary Ingenito,
Chief Medical Officer and Head of Regulatory Affairs -
Patrick J. McEnany,
Co-Founder, Chairman, Pres & CEO -
Dr. Steven R. Miller,
COO & Chief Scientific Officer -
Dr. Gary Ingenito,
Chief Medical & Regulatory Officer -
Alicia Grande,
Chief Accounting Officer, VP, Treasurer & CFO -
Alicia Grande,
Chief Financial Officer, Vice President, Treasurer -
Jeffrey Del Carmen,
Chief Commercial Officer -
Brian Elsbernd,
Chief Compliance Officer, Chief Legal Officer -
Charles O'Keeffe,
Lead Independent Director -
Donald Denkhaus,
Independent Director -
David Tierney,
Independent Director -
Richard Daly,
Independent Director -
Jeffrey Del Carmen,
Chief Commercial Officer -
Philip B. Schwartz,
Corp. Sec. -
Dr. Preethi Sundaram Ph.D.,
Chief Product Devel. Officer -
Pete Curry Sr.,
VP of Sales -
Brian Elsbernd J.D.,
Chief Compliance Officer & Chief Legal Officer -
Mary Coleman,
VP & Head of Investor Relations -
Philip H Coelho,
Director -
Paul J Merrigan,
Chief Commercial Officer -
M Douglas Winship,
V.P. of Regulatory Operations -
Daniel Brennan,
Chief Commercial Officer -
Tamar Thompson,
Director -
David D Muth,
Exec. V.P., Corp. Development -
Hubert E Md Huckel,
Director -
Milton J Wallace,
Director -
Pharmaceutical Inc Biomarin,
10% owner -
Jack Weinstein,
V.P., Treasurer & CFO -
Molly Harper,
Director -
Preethi Sundaram,
Chief Strategy Officer -
Steve Miller,
Chief Op. & Scientific Officer